<DOC>
	<DOCNO>NCT01951846</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) BIBF 1120 patient solid tumour monitor drug-related adverse event . Secondary objective evaluation safety , efficacy , pharmacokinetics , pharmacodynamics .</brief_summary>
	<brief_title>To Determine Maximum Tolerated Dose ( MTD ) BIBF 1120 Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Patients confirm diagnosis advance , non resectable / metastatic solid tumour , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment Evaluable tumour deposit one technique ( Xray , CT , MRI , ultrasound ) Age 18 year old Life expectancy least three month Patients give write informed consent ( must consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) local legislation ) Eastern Cooperative Oncology Group ( ECOG ) performance score &lt; 2 Full recovery therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy History relevant surgical procedure last four week prior treatment trial drug , active ulcer , injury incomplete wound heal Pregnancy breastfeed Active infectious disease Brain metastases require therapy Absolute neutrophil count less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin great 1.5 mg / dl ( &gt; 26 μmol / L , International System Units ( SI unit ) equivalent ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg / dl ( &gt; 132 μmol / L , SI unit equivalent ) Uncontrolled , severe hypertension Gastrointestinal disorder anticipate interfere resorption study drug Serious illness concomitant nononcological disease consider investigator incompatible protocol Women men sexually active unwilling use medically acceptable method contraception Treatment investigational drug participation another clinical trial within past four week start therapy concomitantly trial ( except present trial drug ) Patients unable comply protocol Active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>